https://www.selleckchem.com/products/on123300.html
No severe side effects occurred. In three of four patients, everolimus led to stable disease for the longestcompared to the other nonsurgical therapies used. Comparing the sparse data available everolimus is a promising treatment for t-NEN at least in second-line therapy. A low Ki-67 index was associated with a better outcome. Comparing the sparse data available everolimus is a promising treatment for t-NEN at least in second-line therapy. A low Ki-67 index was associated with a better outcome. To evaluate a criterion for the selective
Мне нравится
Комментарий
Перепост
